Clinical Trials
402
Active:5
Completed:63
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:9
Phase 2:78
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (245 trials with phase data)• Click on a phase to view related trials
Not Applicable
105 (42.9%)Phase 2
78 (31.8%)Phase 4
34 (13.9%)Phase 3
17 (6.9%)Phase 1
9 (3.7%)Early Phase 1
2 (0.8%)VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Not Applicable
Not yet recruiting
- Conditions
- Older PatientsMyeloid MalignanciesConditioningHematopoietic Stem Cell Transplantation (HSCT)
- Interventions
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 160
- Registration Number
- NCT07052422
Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephalitis or Encephalomyelitis
Completed
- Conditions
- Autoimmune Encephalitis
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 300
- Registration Number
- NCT07036042
- Locations
- 🇨🇳
Nanfang hospital, Guangzhou, Guangdong, China
A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
Recruiting
- Conditions
- GastritisGastric DysplasiaGastric UlcerGastric CancerGastric Mass
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 10000
- Registration Number
- NCT07032961
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
Not yet recruiting
- Conditions
- Metastatic Hormone-sensitive Prostate CancerDarolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT07031258
Bronchoalveolar Lavage Combined With High-throughput Sequencing Technology
Completed
- Conditions
- Pneumonia
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 500
- Registration Number
- NCT07005466
- Locations
- 🇨🇳
Guangdong Locations, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 81
- Next
News
No news found